Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of US Medical Affairs Operations will be instrumental in enabling medical impact through operational leadership, strategic planning, process and systems enablement across the full product lifecycle and portfolio. Reporting to the VP, Medical Affairs, this highly visible role drives planning, integration, execution, and governance of medical affairs activities across the US Medical Affairs portfolio. As a core member of the USMA Leadership Team, this role ensures that strategy is translated into coordinated, high-impact execution across US cross-functional stakeholders. This role will collaborate across internal teams and external partners to deliver compliant, efficient, and scalable solutions that support medical strategy, launch readiness, and scientific exchange in the US Region.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director